Fulminant hepatitis due to very severe sinusoidal obstruction syndrome (SOS/VOD) after autologous peripheral stem cell transplantation: a case report

Emmanuelle Tavernier1*, Emilie Chalayer1, Jérôme Cornillon1, Anne Pouvaret1, Jean-Alain Martignoles1, François Casteillo2, Jérémy Terreaux3, Elisabeth Daguenet1 and Denis Guyotat1

Abstract
Background: Hepatic veno-occlusive disease, also called sinusoidal obstruction syndrome (SOS/VOD), is a potentially fatal complication of allogeneic or autologous hematopoietic stem cell transplantation. A plethora of transplant and patient-related risk factors predispose to SOS/VOD and should be taken into account for prognosis assessment as well as for adequate therapeutic intervention.

Case presentation: We describe the case of a mantle cell lymphoma patient who developed a fulminant hepatitis following oxaliplatin-containing intensive chemotherapy and autologous transplantation. This clinical manifestation was secondary to a very severe SOS/VOD. The patient did not exhibit the usual risk factors and presented a non-classical form with major cytolysis, thus puzzling SOS/VOD diagnosis in this context.

Conclusion: SOS has been previously reported after oxaliplatin-based chemotherapy regimens for colorectal cancers, in particular in patients with colorectal liver metastases. We therefore suspected a potential relationship with oxaliplatin-based regimen as a driver of SOS/VOD in a non-susceptible lymphoma patient. With regards to this case, clinicians and especially intensivists should be aware of this atypical presentation.

Keywords: Mantle cell lymphoma, Autologous transplantation, Sinusoidal obstruction syndrome, BEAM regimen, Oxaliplatin, Case report

Background
Sinusoidal obstruction syndrome or veno-occlusive disease (SOS/VOD) is a life-threatening complication following hematopoietic stem cell transplantation (HSCT) with median incidence lower than 10% after autologous HSCT [2]. SOS/VOD pathophysiology results from sinusoidal endothelial cells damage and hepatic injury due to toxic metabolites generated by conditioning chemotherapy and radiotherapy [3]. We presently report the case of a patient who developed a very severe SOS/VOD, as revealed by an unusual increase of transaminase level.

Case presentation
A 59-year-old and overweight man (weight = 87 kg, BMI = 29.75) who suffered from a sleep apnea syndrome, was diagnosed with a stage III mantle cell lymphoma in December 2014. On admission, he presented systemic lymphadenopathy without any bone marrow involvement. Laboratory tests showed normal liver enzymes levels as well as negative hepatitis B and C serological profiles.

An oxaliplatin-based polychemotherapy followed by high-dose therapy and autologous stem cell transplantation was proposed. First-line chemotherapy with four...
cycles of R-DHAX regimen, including rituximab, dexamethasone, cytarabine and oxaliplatin was administered. After three courses, PET-CT (positron emission tomography) response assessment indicated a complete metabolic response. The patient then received conditioning regimen with BEAM 400, consisting of bicnu (300 mg/m²) for 1 day, etoposide (400 mg/m²) combined to cytarabine (400 mg/m²) for 4 days and melphalan (140 mg/m²) for 1 day prior to autologous HSCT. Anti-infective prophylaxis included valacyclovir and fluconazole, starting on Day –7. On March 16th, 2015 (Day 0), 9.8 × 10⁶ cells CD34+/kg were infused. During this procedure, laboratory data did not display any abnormality, especially hepatic enzymes levels that were within the normal range. Despite antimicrobial therapy with Piperacillin–Tazobactam, the patient had persistent fever over the ensuing 72 h, requiring an empiric antifungal treatment with Voriconazole. No signs of invasive aspergillosis were detected (normal CT-scan) and aspergillus antigenemia were negative. Voriconazole was then replaced by Caspofungin on Day +6. On Day +8, oligoanuria was observed and physical examination revealed hepatomegaly, fluid retention, ascites and weight gain < 5% (i.e. 90 kg, +2 kg/48 h). Additionally, thrombocytopenia refractory to platelet transfusion was noted. On Day +9, the serum transaminase concentration increased in an explosive manner from 75 to 2914 UI/L in the evening for aspartate aminotransferase (AST) and from 45 to 1216 UI/L for alanine aminotransferase (ALT). Similarly, the bilirubin level had reached 67 µmol/L (N < 21) accompanied with elevated alkaline phosphatase levels within 24 h (Fig. 1). Alkaline phosphatase levels were initially normal and progressively increased along with SOS/VOD syndrome (2× ULN). The patient developed coagulation disorders as revealed by a progressive increase of INR whereas the Factor V remained normal (Fig. 2). An elevated level of plasminogen activator inhibitor (PAI-1) was also noted with a value of 51 UA/mL (N < 16). An abdominal ultrasound was performed and confirmed hepatomegaly, ascites and decreased velocity in the portal venous flow. The subject whose weight increased more than 5% (i.e. 92 kg) was therefore diagnosed with hepatic VOD and was admitted to the Intensive Care unit. A treatment with Defibrotide at a dose of 25 mg/kg/day was immediately initiated.

Because of the atypical major increase in transaminases levels, a transvenous liver biopsy was performed on Day +10 and showed a patchy perivenulos sinusoidal dilatation and congestion with hepatocyte plate disruption (Fig. 3). A second abdominal ultrasound further supported the diagnosis of SOS/VOD with a worsening of doppler parameters, then harboring a reversed hepatic venous flow. Moreover, differential diagnoses such as fulminant viral hepatitis (hepatitis A, B, C and E, herpes simplex virus, cytomegalovirus, Epstein–Barr virus) were excluded. Despite symptomatic measures along with the maintenance of an adequate fluid balance and ascites removal with albumin infusion, renal failure could not be controlled. Because of anuria, hemodialysis was thus implemented on Day +9.

Neutrophils recovery was achieved on Day +11 and liver dysfunction gradually improved from Day +13 to Day +15 with decreased transaminases levels ([AST] 408 UI/L; [ALT] 494 UI/L) (Fig. 1). Although his overall condition was progressively recovering, the patient presented a sudden hemodynamic instability with an acute respiratory distress syndrome requiring mechanical ventilation, on Day +16. A fulminant liver failure with uncontrolled lactic acidosis was observed. An abdominal CT scan was performed and showed an acute mesenteric ischemia with hepatic and renal ischemic injury. The

![Fig. 1](image1.png)

**Fig. 1** Laboratory data during the clinical course from Day −7 (D −7) to Day +16 (D +16): hepatic enzymes with AST, ALT and total bilirubin. The reference day corresponds to the autologous transplantation (Day 0, depicted with the arrow 1). Defibrotide treatment was initiated on Day +9 in the evening (D +9PM, depicted with the arrow 2)

![Fig. 2](image2.png)

**Fig. 2** Laboratory data during the clinical course from Day −7 (D −7) to Day +16 (D +16): coagulation factor with Factor V and INR
Discussions and conclusions

SOS/VOD is a dramatic complication observed after HSCT and is associated with a high mortality rate in the most severe forms. This case is of particular interest as it is uncommon. So far, it is the first reported fulminant hepatitis induced by SOS/VOD.

A number of pre-transplant factors and transplantation-related risk factors predispose to SOS/VOD occurrence and are well-documented in the literature [4]. In fact, patient and diseases-related features include older age, female gender, Karnofsky score below 90% and advanced disease. Moreover, the risk of SOS/VOD is higher after allo-HSCT by comparison with autologous transplantation. In the current case, the patient did not present the usual risk factors and was not suffering from an underlying liver disease before transplant (normal serum transaminase level, no active viral hepatitis). Besides, the patient who achieved a first complete remission was not heavily pre-treated before autologous HSCT. One can consider about the potential hepatotoxicity of azole antifungal agents. It is yet important to note that the patient was not treated with azole agents at the time of SOS/VOD signs. More interestingly, we can discuss about the possible role of oxaliplatin before transplant. Indeed, SOS has been previously reported after oxaliplatin-based chemotherapy regimens for colorectal cancers, in particular in patients with colorectal liver metastases [5].

Our patient experienced a very severe SOS/VOD without classical risk factors. The diagnosis should be considered in a patient who develops a “fulminant hepatitis” after an intensive chemotherapy since early intervention could improve outcome. One should pay particular attention to this atypical presentation in order to dispense optimal care.

Abbreviations

SOS: sinusoidal obstruction syndrome; VOD: veno-occlusive disease; HSCT: hematopoietic stem cell transplantation; PET-CT: positron emission tomography; ULN: upper limit of normal; AST: aspartate aminotransferase; ALT: alanine aminotransferase; PAI-1: plasminogen activator inhibitor-1; EBMT: European Society for Blood and Marrow Transplantation.
Authors' contributions
ET conceived and researched the study. ET, ED drafted the manuscript. FC performed the histological examination. JT took care of the patient’s management. ET, EC, JC, JT, AP, JAM, ED and DG performed the literature review and reviewed the manuscript. All authors read and approved the final manuscript.

Author details
1 Department of Clinical Hematology, Institut de Cancérologie Lucien Neuwirth, 108 Bis Avenue Albert Raimond, 42270 Saint Priest en Jarez, France. 2 Department of Pathology, University Hospital, Saint Etienne, France. 3 Intensive Care Unit, University Hospital, Saint Etienne, France.

Acknowledgements
None.

Competing interests
The authors declare that they have no competing interests.

Availability of data and materials
The data supporting the conclusions of this article is included within the article.

Consent for publication
Written informed consent was obtained from the patient.

Consent for publication
Not applicable for case reports.

Funding
All authors received no specific funding for the report.

Ethics approval and consent to participate
Written informed consent was obtained from the patient.

Funding
Not applicable for case reports.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Received: 30 November 2017   Accepted: 26 June 2018
Published online: 03 July 2018

References
1. Carreras E, Bertz H, Arcese W, Vernant JP, et al. Incidence and outcome of hepatic veno-occlusive disease after blood or marrow transplantation: a prospective cohort study of the European Group for Blood and Marrow Transplantation. European Group for Blood and Marrow Transplantation Chronic Leukemia Working Party. Blood. 1998;92(10):3599–604.
2. Carreras E, Diaz-Ricart M. The role of the endothelium in the short-term complications of hematopoietic SCT. Bone Marrow Transplant. 2011;46(12):1495–502.
3. Coppell JA, Richardson PG, Soiffer R, Martin PL, et al. Hepatic veno-occlusive disease following stem cell transplantation: incidence, clinical course, and outcome. Biol Blood Marrow Transplant. 2010;16(2):157–68.
4. Mohty M, Malard M, Abecassis M, Aerts E, et al. Revised diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a new classification from the European Society for Blood and Marrow Transplantation. Bone Marrow Transplant. 2016;51(7):906–12.
5. Rubbia-Brandt L, Audard V, Sartoretti P, Roth AD, et al. Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol. 2004;15(3):460–6.
6. Lignon J, Sibon D, Madelaine I, Brice P, et al. Rituximab, dexamethasone, cytarabine, and oxaliplatin (R-DHAX) is an effective and safe salvage regimen in relapsed/refractory B-cell non-Hodgkin lymphoma. Clin Lymphoma Myeloma Leuk. 2010;10(4):262–9.
7. Tixier F, Ranchon F, Ilits A, Vantard N, et al. Comparative toxicities of 3 platinum-containing chemotherapy regimens in relapsed/refractory lymphoma patients. Hematol Oncol. 2016. https://doi.org/10.1002/hon.2328.
8. Salat C, Holler E, Kolb HJ, Reinhardt B, et al. Plasminogen activator inhibitor-1 confirms the diagnosis of hepatic veno-occlusive disease in patients with hyperbilirubinemia after bone marrow transplantation. Blood. 1997;89(6):2184–8.
9. Park YD, Yasui M, Yoshimoto T, Chayama K, et al. Changes in hemostatic parameters in hepatic veno-occlusive disease following bone marrow transplantation. Bone Marrow Transplant. 1997;19(9):915–20.
10. Mahgerefteh S1, Sosna J, Bogot N, Shapira MY, et al. Radiologic imaging and intervention for gastrointestinal and hepatic complications of hematopoietic stem cell transplantation. Radiology. 2011;258(3):660–71.
11. Richardson PG, Riches ML, Kernan NA, Brochstein JA, et al. Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure. Blood. 2016;127(13):1656–65.
12. Carreras E. How I manage sinusoidal obstruction syndrome after haematopoietic cell transplantation. Br J Haematol. 2015;168(4):481–91.
13. Dignan FL, Wynne RF, Hadzic N, Karani J, et al. BCSH/BBSMT guideline: diagnosis and management of veno-occlusive disease (sinusoidal obstruction syndrome) following haematopoietic stem cell transplantation. Br J Haematol. 2013;163(4):444–57.
14. Chao N. How I treat sinusoidal obstruction syndrome. Blood. 2014;123(26):4023–6.
15. Richardson PG, Smith AR, Triplett BM, Kernan NA, et al. Earlier defibrotide initiation post-diagnosis of veno-occlusive disease/sinusoidal obstruction syndrome improves Day +100 survival following haematopoietic stem cell transplantation. Br J Haematol. 2017;178(1):112–8.